OBJECTIVE The aim of the study was to elucidate the differential metabolic activities in aggressive and indolent subtypes of uterine sarcomas, which may aid in managing these heterogeneous tumours. METHODS We retrospectively analysed the PET/computed tomography scans of consecutive patients (N=18) diagnosed with uterine sarcoma at our unit. The patients were divided into indolent (N=4) and ag...

BACKGROUND Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. METHODS We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Libra...

Pancreatic neuroendocrine tumors are usually indolent (slow-growing) by nature and develop over the course of many years. Pancreatic neuroendocrine tumors are usually more indolent, with better prognosis than adenocarcinoma of the pancreas (Carriaga & Henson, 1995). However, aggressive, fast growing pancreatic neuroendocrine tumors exist and different types of pancreatic neuroendocrine tumors e...

We present a patient with isolated intracranial mucormycosis that remained indolent for several months. The mucormycosis formed a mass in the prepontine cistern, probably spreading from the sphenoid sinus. We propose that at least some cases of what is considered isolated CNS mucormycosis develop from such unrecognized indolent infections. Mucormycosis may present as a mass in the basilar ciste...

The prognostic role of the transcription factor SOX11 in mantle cell lymphoma (MCL) is controversial. We investigated prognostic markers in a population-based cohort of 186 MCL cases. Seventeen patients (9%) did not require any therapy within the first 2 years after diagnosis and were retrospectively defined as having an indolent disease. As expected, indolent MCL had less frequent B symptoms a...

BACKGROUND Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a long time without any treatment. The process of "wait and watch" leaves these patients with the potential risk of evolution to classic, aggres...

Low-grade rash may occur with lenalidomide, rituximab, or their combination (R) in non-Hodgkin lymphoma (NHL). From our phase II study of R in previously untreated indolent lymphoma (n=110), 52 (47%) patients had rash, which was associated with pruritus in 22 (42%). Worst grade 1, 2, and 3 rash was found in 19%, 21%, and 7%, respectively. Grade 1/2 rash was effectively managed with observation,...

The long-term prognosis of indolent adult T-cell leukemia-lymphoma (ATL) is not clearly elucidated. From 1974 to 2003, newly diagnosed indolent ATL in 90 patients (65 chronic type and 25 smoldering type) was analyzed. The median survival time was 4.1 years; 12 patients remained alive for more than 10 years, 44 progressed to acute ATL, and 63 patients died. The estimated 5-, 10-, and 15-year sur...

Primary gastrointestinal (GI) T- and NK-cell lymphomas are usually aggressive neoplasms associated with high morbidity and mortality. Over the past two decades, however, cases of primary GI lymphoproliferative disorders (LPDs) or lymphomas of T- or NK-cell derivation with indolent behavior have been reported. These LPDs are rare and they can be challenging to diagnose as they share clinical and...

Primary retroperitoneal malignant lymphoma is rare, and primary retroperitoneal indolent B-cell lymphoma has not been reported. A 64-year-old woman presented anuria. Imaging techniques showed large retroperitoneal mass, and biopsies from it revealed non-Hodgkin indolent B-cell lymphoma (small lymphocytic lymphoma/chronic lymphocytic lymphoma). The tumor appeared retroperitoneal primary and extr...